RUA Life Sciences has a Cash Ratio of 7.09. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for RUA Life Sciences's Cash Ratio or its related term are showing as below:
FRA:AOHA'
s Cash Ratio Range Over the Past 10 Years
Min: 1.11 Med: 5.18 Max: 24.36
Current: 7.1
During the past 13 years, RUA Life Sciences's highest Cash Ratio was 24.36. The lowest was 1.11. And the median was 5.18.
FRA:AOHA's Cash Ratio is ranked better than 90.56% of 858
companies
in the Medical Devices & Instruments industry
Industry Median: 1.11
vs FRA:AOHA: 7.10
RUA Life Sciences Cash Ratio Historical Data
The historical data trend for RUA Life Sciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RUA Life Sciences's Cash Ratio
For the Medical Devices subindustry, RUA Life Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Cash Ratio falls into.
RUA Life Sciences Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
RUA Life Sciences's Cash Ratio for the fiscal year that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
RUA Life Sciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of RUA Life Sciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AOHA has been successfully added to your 